Chronic Fatigue Syndrome Presents Challenging Test Case For PDUFA V Program
This article was originally published in The Pink Sheet Daily
The first of 20 patient-focused drug development meetings kicks off April 25 with a workshop on CFS and myalgic encephalomyelitis; FDA can expect to hear extensive patient testimony about an array of symptoms and co-morbid conditions, as well as some dissension within the patient community over how the two conditions should be viewed.
You may also be interested in...
FDA has selected CFS/ME as the first topic for the PDUFA V patient-centered drug development initiative. The lessons learned from this session will inform future work on patient engagement in drug development both for FDA—and for patient advocates.
December’s Arthritis Advisory Committee review of Hemispherx’s drug provided FDA with the first public opportunity to explain in detail why the chronic fatigue syndrome drug, in development for almost 25 years, has not passed regulatory muster to date.
Division of Mitigation Assessment and Medication Error Surveillance will be established within the Office of Surveillance and Epidemiology, a change aimed at strengthening postmarketing oversight of opioids and other drugs; new Office of Safety and Clinical Evaluation will be created in Office of Generic Drugs, where Orange Book staff also will get their own division.